EBIT at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Plus components not separately reported this period.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's EBIT?
- Neurocrine Biosciences (NBIX) reported EBIT of $193.4M in Q1 2026.
- How has Neurocrine Biosciences's EBIT changed year-over-year?
- Neurocrine Biosciences's EBIT increased by 719.5% year-over-year, from $23.6M to $193.4M.
- What is the long-term trend for Neurocrine Biosciences's EBIT?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's EBIT has grown at a 35.5% compound annual growth rate (CAGR), from $249M to $619.1M.
- What does EBIT mean?
- Profit before interest and taxes — the business's core earning power.
- How do you interpret EBIT?
- Higher is better. Because it adds back interest, EBIT compares earning power across firms with very different debt loads — the base for interest coverage and the EV/EBIT multiple. For filers reporting operating income it equals that line, excluding non-operating swings.
- How does EBIT compare across companies?
- Comparable across companies regardless of leverage or tax domicile; the standard 'earning power' line for cross-company analysis. Least meaningful for banks and insurers.